- $1.09bn
- $1.10bn
- $187.34m
- 86
- 17
- 99
- 76
Annual income statement for Axogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 112 | 127 | 139 | 159 | 187 |
| Cost of Revenue | |||||
| Gross Profit | 88.4 | 102 | 111 | 125 | 142 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 135 | 153 | 168 | 180 | 191 |
| Operating Profit | -23.2 | -25.4 | -29.7 | -21.5 | -3.29 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23.8 | -27 | -28.9 | -21.7 | -9.96 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.8 | -27 | -28.9 | -21.7 | -9.96 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.8 | -27 | -28.9 | -21.7 | -9.96 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.8 | -27 | -28.9 | -21.7 | -9.96 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.595 | -0.655 | -0.688 | -0.506 | -0.225 |